MIAMI, FL USA (UroToday.com) - The efficacy of fesoterodine was assessed in patients with refractory OAB symptoms after treatment for BPH. This was a single-center pilot study of 18 male patients > 40 years of age who had bladder outlet obstruction, treated surgically, at least one month prior.
Primary endpoint was a change in International Prostate Symptom Score (IPSS) with secondary endpoints maximum urine flow rates and PVR. Fesoterodine significantly improved IPSS compared to baseline. Adverse events were: 3 (17%) patients had constipation, 1 (6%) with vision change, and 2 (11%) with dry mouth.
Presented by Lily C. Wang, Bilal Chughtai, Asha E. Jamzadeh, Richard K. Lee, Steven A. Kaplan, and Alexis E. Te at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Winter Meeting - February 25 - March 1, 2014 - Doral Golf Resort and Spa - Miami, Florida USA
Reported for UroToday.com by Diane K. Newman, DNP, FAAN, BCB-PMD